PharmAbcine’s e-poster presentation is currently available at Society for Immunotherapy of Cancer (SITC) 2022 website.

The e-poster includes new data of PMC-309, one of the Company’s first immuno-oncology assets. Through the newly presented PK and GLP-Tox data demonstrate that the molecule has its safety profile established and is ready for the entry into clinical trial.

The registered members may access the poster on the SITC website virtual platform (https://2022.sitc.showcare.io/). The details of the presentation are as follows:

Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

Abstract Number: 751

Presentation Type: Poster Presentation

Onsite Location: Poster Hall

■ Please check the attached files for full texts and summary of the presentation.